| Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma |
NCT06208540: Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants |
|
|
| Completed | 4 | 150 | RoW | Cerebrolysin, olfactory and gustatory trainings | Sherifa Ahmed Hamed | Post-covid-19 Persistent Smell and Taste Disorders | 04/24 | 05/24 | | |
MI22-00013, NCT06273020: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke |
|
|
| Recruiting | 4 | 60 | RoW | Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin | Hospital Universitario Dr. Jose E. Gonzalez, Ever Neuro Pharma GmbH | Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier | 11/24 | 12/24 | | |
NCT04913831: Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study |
|
|
| Recruiting | 4 | 30 | RoW | Cerebrolysin, Placebo | Yonsei University | Stroke | 03/24 | 03/24 | | |
| Recruiting | 4 | 350 | Europe | Cerebrolysin, FPF (Fine Particle Fraction)-1070 | Poznan University of Medical Sciences | Acute Ischemic Stroke | 01/25 | 03/25 | | |
NCT04427241: Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness |
|
|
| Not yet recruiting | 4 | 12 | RoW | Cerebrolysin, Control | Konkuk University Medical Center, Ever Neuro Pharma GmbH | Disorder of Consciousness, Hemorrhagic Stroke | 07/25 | 12/25 | | |
